Patient characteristics (n = 85)
| Median age, y (range) . | 48 (10-67) . |
|---|---|
| Patient sex | |
| Female | 42 (49%) |
| Male | 43 (51%) |
| Patient/donor sex | |
| Sex match | 43 (50.6%) |
| Female/male | 21 (24.7%) |
| Male/female | 21 (24.7%) |
| Disease risk* | |
| High | 39 (46%) |
| Low | 46 (54%) |
| Diagnosis | |
| AML | 33 (39%) |
| ALL | 18 (21%) |
| non-Hodgkin lymphoma | 11 (13%) |
| MDS | 6 (7%) |
| CML | 5 (6%) |
| Hodgkin lymphoma | 4 (5%) |
| Myeloproliferative disorder | 4 (5%) |
| Multiple myeloma | 3 (3%) |
| CLL | 1 (1%) |
| Recipient CMV serostatus positive/negative | 64/21 |
| Prior autologous transplant | 6 (7%) |
| Stem cell source | |
| Bone marrow | 5 (6%) |
| Peripheral blood | 80 (94%) |
| CD34+ cell dose x106/kg: median (range) | 5.1 (1.7-10.5) |
| Conditioning regimen | |
| Flu/Mel | 46 (54%) |
| TBI/VP16 | 28 (33%) |
| Bu/Cy | 11 (13%) |
| Median age, y (range) . | 48 (10-67) . |
|---|---|
| Patient sex | |
| Female | 42 (49%) |
| Male | 43 (51%) |
| Patient/donor sex | |
| Sex match | 43 (50.6%) |
| Female/male | 21 (24.7%) |
| Male/female | 21 (24.7%) |
| Disease risk* | |
| High | 39 (46%) |
| Low | 46 (54%) |
| Diagnosis | |
| AML | 33 (39%) |
| ALL | 18 (21%) |
| non-Hodgkin lymphoma | 11 (13%) |
| MDS | 6 (7%) |
| CML | 5 (6%) |
| Hodgkin lymphoma | 4 (5%) |
| Myeloproliferative disorder | 4 (5%) |
| Multiple myeloma | 3 (3%) |
| CLL | 1 (1%) |
| Recipient CMV serostatus positive/negative | 64/21 |
| Prior autologous transplant | 6 (7%) |
| Stem cell source | |
| Bone marrow | 5 (6%) |
| Peripheral blood | 80 (94%) |
| CD34+ cell dose x106/kg: median (range) | 5.1 (1.7-10.5) |
| Conditioning regimen | |
| Flu/Mel | 46 (54%) |
| TBI/VP16 | 28 (33%) |
| Bu/Cy | 11 (13%) |
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; and CLL, chronic lymphocytic leukemia.
Low-risk disease is defined as acute leukemia in first remission, chronic myeloid leukemia in chronic phase, myeloproliferative disorders, and low-grade myelodysplastic syndrome (RA/RARS).